Medpace (NASDAQ:MEDP) CEO August Troendle Sells 3,510 Shares of Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 3,510 shares of the stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $600.01, for a total value of $2,106,035.10. Following the sale, the chief executive officer directly owned 638,946 shares in the company, valued at $383,373,989.46. This represents a 0.55% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Medpace Price Performance

Medpace stock opened at $585.49 on Thursday. The firm has a market cap of $16.34 billion, a PE ratio of 34.32, a price-to-earnings-growth ratio of 2.55 and a beta of 1.15. The stock’s fifty day moving average price is $501.76 and its two-hundred day moving average price is $493.30. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company’s revenue was up 17.2% compared to the same quarter last year. During the same period in the prior year, the company posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Sell-side analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of MEDP. BOKF NA boosted its holdings in shares of Medpace by 0.8% during the 3rd quarter. BOKF NA now owns 2,542 shares of the company’s stock valued at $1,307,000 after acquiring an additional 20 shares in the last quarter. Valeo Financial Advisors LLC increased its holdings in Medpace by 5.0% in the 4th quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock worth $249,000 after purchasing an additional 21 shares in the last quarter. UMB Bank n.a. increased its holdings in Medpace by 5.6% in the 4th quarter. UMB Bank n.a. now owns 450 shares of the company’s stock worth $253,000 after purchasing an additional 24 shares in the last quarter. Schulhoff & Co. Inc. raised its position in Medpace by 1.1% in the fourth quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock valued at $1,237,000 after purchasing an additional 25 shares during the last quarter. Finally, Balefire LLC raised its position in Medpace by 6.1% in the first quarter. Balefire LLC now owns 451 shares of the company’s stock valued at $217,000 after purchasing an additional 26 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on MEDP shares. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $535.00 target price on shares of Medpace in a report on Thursday, July 23rd. Leerink Partners set a $620.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Royal Bank Of Canada upped their target price on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Jefferies Financial Group cut Medpace from a “buy” rating to a “hold” rating and boosted their price target for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. Finally, Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Two research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $584.18.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.